285 related articles for article (PubMed ID: 28072764)
61. Pruritic arthropod bite-like papules in T-cell large granular lymphocytic leukaemia and chronic myelomonocytic leukaemia.
Lewis DJ; Miranda RN; Oh CW; Hinojosa T; Medeiros LJ; Curry JL; Tetzlaff MT; Torres-Cabala CA; Nagarajan P; Ravandi-Kashani F; Duvic M
Clin Exp Dermatol; 2018 Jun; 43(4):449-453. PubMed ID: 29423961
[TBL] [Abstract][Full Text] [Related]
62. The intriguing patterns of tumor response to trabectedin.
Sanfilippo R; Casali PG
Expert Rev Anticancer Ther; 2013 Jun; 13(6 Suppl 1):21-4. PubMed ID: 23638727
[TBL] [Abstract][Full Text] [Related]
63. Serotonin receptor type 1B constitutes a therapeutic target for MDS and CMML.
Banús-Mulet A; Etxabe A; Cornet-Masana JM; Torrente MÁ; Lara-Castillo MC; Palomo L; Nomdedeu M; Díaz-Beyá M; Solé F; Nomdedeu B; Esteve J; Risueño RM
Sci Rep; 2018 Sep; 8(1):13883. PubMed ID: 30224768
[TBL] [Abstract][Full Text] [Related]
64. A retrospective analysis of antitumour activity with trabectedin in translocation-related sarcomas.
Le Cesne A; Cresta S; Maki RG; Blay JY; Verweij J; Poveda A; Casali PG; Balaña C; Schöffski P; Grosso F; Lardelli P; Nieto A; Alfaro V; Demetri GD
Eur J Cancer; 2012 Nov; 48(16):3036-44. PubMed ID: 22749255
[TBL] [Abstract][Full Text] [Related]
65. Methylation status of the p15 and p16 genes in paediatric myelodysplastic syndrome and juvenile myelomonocytic leukaemia.
Hasegawa D; Manabe A; Kubota T; Kawasaki H; Hirose I; Ohtsuka Y; Tsuruta T; Ebihara Y; Goto Y; Zhao XY; Sakashita K; Koike K; Isomura M; Kojima S; Hoshika A; Tsuji K; Nakahata T
Br J Haematol; 2005 Mar; 128(6):805-12. PubMed ID: 15755284
[TBL] [Abstract][Full Text] [Related]
66. Trabectedin in soft tissue sarcomas.
Brodowicz T
Future Oncol; 2014 Jun; 10(8 Suppl):s1-5. PubMed ID: 25048043
[TBL] [Abstract][Full Text] [Related]
67. Juvenile myelomonocytic leukemia.
Emanuel PD
Curr Hematol Rep; 2004 May; 3(3):203-9. PubMed ID: 15087069
[TBL] [Abstract][Full Text] [Related]
68. Prognostic significance of SETBP1 mutations in myelodysplastic syndromes, chronic myelomonocytic leukemia, and chronic neutrophilic leukemia: A meta-analysis.
Shou LH; Cao D; Dong XH; Fang Q; Wu Y; Zhang Y; Fei JP; Xu BL
PLoS One; 2017; 12(2):e0171608. PubMed ID: 28158286
[TBL] [Abstract][Full Text] [Related]
69. Sustained MEK inhibition abrogates myeloproliferative disease in Nf1 mutant mice.
Chang T; Krisman K; Theobald EH; Xu J; Akutagawa J; Lauchle JO; Kogan S; Braun BS; Shannon K
J Clin Invest; 2013 Jan; 123(1):335-9. PubMed ID: 23221337
[TBL] [Abstract][Full Text] [Related]
70. Targeted Next-Generation Sequencing in Myelodysplastic Syndrome and Chronic Myelomonocytic Leukemia Aids Diagnosis in Challenging Cases and Identifies Frequent Spliceosome Mutations in Transformed Acute Myeloid Leukemia.
Reinig E; Yang F; Traer E; Arora R; Brown S; Rattray R; Braziel R; Fan G; Press R; Dunlap J
Am J Clin Pathol; 2016 Apr; 145(4):497-506. PubMed ID: 27124934
[TBL] [Abstract][Full Text] [Related]
71. Deficiency of β Common Receptor Moderately Attenuates the Progression of Myeloproliferative Neoplasm in NrasG12D/+ Mice.
Zhang J; Ranheim EA; Du J; Liu Y; Wang J; Kong G; Zhang J
J Biol Chem; 2015 Jul; 290(31):19093-103. PubMed ID: 26082490
[TBL] [Abstract][Full Text] [Related]
72. Going further in the knowledge of Yondelis®; what's new in clinical trials?
Blay JY
Future Oncol; 2014 Jun; 10(8 Suppl):s7-s12. PubMed ID: 25048046
[TBL] [Abstract][Full Text] [Related]
73. Trabectedin in patients with advanced non-small-cell lung cancer (NSCLC) with XPG and/or ERCC1 overexpression and BRCA1 underexpression and pretreated with platinum.
Massuti B; Cobo M; Camps C; Dómine M; Provencio M; Alberola V; Viñolas N; Rosell R; Tarón M; Gutiérrez-Calderón V; Lardelli P; Alfaro V; Nieto A; Isla D
Lung Cancer; 2012 Jun; 76(3):354-61. PubMed ID: 22197612
[TBL] [Abstract][Full Text] [Related]
74. Third-line trabectedin for a metastatic desmoplastic small round cell tumour treated with multimodal therapy.
Brunetti AE; Delcuratolo S; Lorusso V; Palermo L; Di Giorgio A; Pisconti S; Silvestris N
Anticancer Res; 2014 Jul; 34(7):3683-8. PubMed ID: 24982387
[TBL] [Abstract][Full Text] [Related]
75. Results of sub-analysis of a phase 2 study on trabectedin treatment for extraskeletal myxoid chondrosarcoma and mesenchymal chondrosarcoma.
Morioka H; Takahashi S; Araki N; Sugiura H; Ueda T; Takahashi M; Yonemoto T; Hiraga H; Hiruma T; Kunisada T; Matsumine A; Susa M; Nakayama R; Nishimoto K; Kikuta K; Horiuchi K; Kawai A
BMC Cancer; 2016 Jul; 16():479. PubMed ID: 27418251
[TBL] [Abstract][Full Text] [Related]
76. Panobinostat inhibits the proliferation of CD34
Kurata T; Matsuda K; Hirabayashi K; Shigemura T; Sakashita K; Nakahata T; Koike K
Pediatr Blood Cancer; 2018 Nov; 65(11):e27261. PubMed ID: 30014555
[TBL] [Abstract][Full Text] [Related]
77. Cutting the cord from myelodysplastic syndromes: chronic myelomonocytic leukemia-specific biology and management strategies.
Padron E; Steensma DP
Curr Opin Hematol; 2015 Mar; 22(2):163-70. PubMed ID: 25575034
[TBL] [Abstract][Full Text] [Related]
78. Recent advances in the pathogenesis and management of juvenile myelomonocytic leukaemia.
Koike K; Matsuda K
Br J Haematol; 2008 May; 141(5):567-75. PubMed ID: 18422786
[TBL] [Abstract][Full Text] [Related]
79. Activity of 9-nitro-camptothecin, an oral topoisomerase I inhibitor, in myelodysplastic syndrome and chronic myelomonocytic leukemia.
Quintas-Cardama A; Kantarjian H; O'Brien S; Jabbour E; Giles F; Ravandi F; Faderl S; Pierce S; Shan J; Verstovsek S; Cortes J
Cancer; 2006 Oct; 107(7):1525-9. PubMed ID: 16955510
[TBL] [Abstract][Full Text] [Related]
80. Targeting cell-bound MUC1 on myelomonocytic, monocytic leukemias and phenotypically defined leukemic stem cells with anti-SEA module antibodies.
Guillaume T; Dehame V; Chevallier P; Peterlin P; Garnier A; Grégoire M; Pichinuk E; Rubinstein DB; Wreschner DH
Exp Hematol; 2019 Feb; 70():97-108. PubMed ID: 30593830
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
